



## **Eleven Biotherapeutics to Present at the LD Micro Main Event 2017**

November 30, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 30, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurlly, President and Chief Executive Officer, will present a company overview at the LD Micro Main Event 2017 in Los Angeles, CA on Thursday, December 7, 2017 at 8:30 a.m. PST.

A live webcast can be accessed from the Investors & Media section of Eleven's website, [www.elevenbio.com](http://www.elevenbio.com). An archived replay of the webcast will be available on the Company's website for 90 days after the conference.

### **About Eleven Biotherapeutics**

Eleven Biotherapeutics, Inc. is a late-stage, clinical oncology company advancing novel product candidates based upon the Company's targeted protein therapeutics (TPTs) platform. TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. Eleven's lead TPT, Vicinium, is currently in a Phase 3 trial in non-muscle invasive bladder cancer, with topline three-month data expected in mid-2018. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistant mechanisms. Additionally, the Company believes that its TPT's cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more information, please refer to the Company's website at [www.elevenbio.com](http://www.elevenbio.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171130006163/en/>

Source: Eleven Biotherapeutics, Inc.

Stern Investor Relations, Inc.  
Michael Schaffzin, 212-362-1200  
[michael@sternir.com](mailto:michael@sternir.com)